Patents Assigned to Laboratoires des Produits Ethiques Ethypharm
-
Publication number: 20080248101Abstract: A pharmaceutical composition containing fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose reduces food effect. The cellulose derivative represents less than 20 wt. % of the composition. The association of fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enhances the bioavailability of fenofibrate. Also provided is a method for preparing said composition without organic solvent.Type: ApplicationFiled: June 11, 2008Publication date: October 9, 2008Applicant: SOCIETE LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Publication number: 20070071812Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: ApplicationFiled: August 25, 2006Publication date: March 29, 2007Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Patent number: 7101574Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: GrantFiled: July 7, 2000Date of Patent: September 5, 2006Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Patent number: 6967028Abstract: The present invention provides microspheres intended to be administered by injection comprising a protein active ingredient and an agent coating the active ingredient intended to prolong its release, wherein they are free of any trace of organic solvent and they can be obtained according to a coating method involving bringing the active ingredient and the coating agent into contact, with stirring, in a supercritical fluid, said coating agent being soluble in this supercritical fluid.Type: GrantFiled: June 5, 2001Date of Patent: November 22, 2005Assignees: Mainelab, Laboratoires des Produits Ethiques EthypharmInventors: Claire Dulieu, Joël Richard, Jean-Pierre Benoit
-
Patent number: 6951657Abstract: The invention concerns coated particles based on granulated microcrystals of ibuprofen, its pharmaceutically acceptable isomers and salts, characterized in that they comprise a coating obtained in a fluidized bed apparatus with a hydroalcoholic dispersion consisting of a mixture comprising (A) 5 to 50% by weight of ethylcellulose relative to ibuprofen; (B) 10 to 60% by weight of hydroxypeopylmethylcellulose relative to the ethylcellulose; and (C) 1 to 40% by weight of silica with antistatic and permeabilizing properties relative to the ethylcellulose, the resulting coating, whereof at least one of the constituents can be used for granulating the ibuprofen microcrystals resulting in said particles, thereby masking the unpleasant taste of ibuprofen and significantly reducing its irritating effect on the throat after deglutition and substantially immediate release of ibuprofen when the particles are placed in an aqueous medium.Type: GrantFiled: November 3, 1999Date of Patent: October 4, 2005Assignee: Laboratoires des produits Ethiques Ethypharm SAInventors: Jean-Marc Zuccarelli, Charles André Chauveau, Gilles DeMichelis, Karine Jean
-
Patent number: 6803052Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: GrantFiled: November 16, 2001Date of Patent: October 12, 2004Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Patent number: 6794411Abstract: The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.Type: GrantFiled: November 6, 2001Date of Patent: September 21, 2004Assignee: Laboratoire des Produits Ethiques EthypharmInventors: Christophe Lebon, Emmanuel Guerin, Pascal Suplie
-
Patent number: 6770298Abstract: The invention concerns a device for producing granules, in particular pharmaceutical granules, comprising a drum (4) with peripheral apertures (25) and a member (30) feeding the drum with coating or fixing substance. The drum (4) comprises mutually parallel sections (22) defining between them the apertures (25).Type: GrantFiled: August 9, 2000Date of Patent: August 3, 2004Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Patrice Romain
-
Publication number: 20030175356Abstract: The invention relate to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from, or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres use preferably contain 5-fluorouracile coated with poly(d-l-lactic acid-co-glycolic acid). The microspheres are implanted in the walls of the operation site following the exeresis of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: ApplicationFiled: March 18, 2003Publication date: September 18, 2003Applicant: Laboratoires Des Produits Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Patent number: 6613361Abstract: The invention concerns ketoprofen microgranules with prolonged release each consisting of an active core containing ketoprofen coated with a polymeric film enabling prolonged release of the active principle and containing acrylic polymer coatings in a volume proportion substantially equal to 90/10.Type: GrantFiled: November 15, 2001Date of Patent: September 2, 2003Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Christophe Lebon, Dominique Marechal, Pascal Suplie
-
Publication number: 20030129244Abstract: The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules.Type: ApplicationFiled: September 30, 2002Publication date: July 10, 2003Applicant: Laboratoires Des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Publication number: 20030017210Abstract: The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.Type: ApplicationFiled: July 25, 2002Publication date: January 23, 2003Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Publication number: 20020182253Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).Type: ApplicationFiled: December 3, 2001Publication date: December 5, 2002Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 6482437Abstract: The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules. Each microgranule comprises a neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose, which represents 10 to 50% by weight of the morphine sulfate/binder mixture. The present invention also relates to a process for the preparation of these microgranules which is carried out entirely in aqueous medium on neutral support grains. The present invention finally relates to the pharmaceutical preparations comprising the microgranules according to the invention.Type: GrantFiled: February 16, 1999Date of Patent: November 19, 2002Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 6458389Abstract: The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.Type: GrantFiled: September 8, 1999Date of Patent: October 1, 2002Assignee: Laboratoires Des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 6383516Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).Type: GrantFiled: January 11, 2001Date of Patent: May 7, 2002Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
-
Publication number: 20020051749Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: ApplicationFiled: November 16, 2001Publication date: May 2, 2002Applicant: Laboratoires Des Produits Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Publication number: 20020012679Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.Type: ApplicationFiled: February 5, 2001Publication date: January 31, 2002Applicant: Societe Laboratoires des Produits Ethiques - EthypharmInventors: Etienne Bruna, Edouard Gendrot, Charles Chauveau, Alain-Gilles Demichelis
-
Patent number: 6139877Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing tiagabine as active principle. The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids. These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the tiagabine contained in the spheroids following a possible compression step.Type: GrantFiled: November 23, 1998Date of Patent: October 31, 2000Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 5549911Abstract: The present invention relates to a galenic form of 5-nitroimidazole derivatives which is characterized in that it comprises a combination of microgranules of 5-nitroimidazole derivatives consisting, on the one hand, of gastroresistant microgranules and, on the other hand, of prolonged-release microgranules, the pharmaceutical compositions comprising them and the microgranules as intermediates in the preparation of the form according to the invention.Type: GrantFiled: January 11, 1995Date of Patent: August 27, 1996Assignee: Laboratoires Des Produits Ethiques EthypharmInventors: Gerard Leduc, Patrice Debregeas